Jun Li
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Jun Li has a total of 8 co-authors. Here are the top co-authors by number of shared publications:
- Fei Bian
Institute of Crop Germplasm Resources, Shandong Academy of Agricultural Sciences, Jinan 250100, China
2 shared publications - Gao Chen
State Key Laboratory of Nutrient Use and Management, Shandong Academy of Agricultural Sciences, Jinan, China
2 shared publications - Jean-François Picimbon
Shandong Academy of Agricultural Sciences, Jinan 250100, China
2 shared publications - Shousong Yue
Shandong Academy of Agricultural Sciences, Jinan 250100, China
2 shared publications - Yan Zhang
Institute of Crop Germplasm Resources, Shandong Academy of Agricultural Sciences, Jinan 250100, China
2 shared publications - Youfeng Zhu
Institute of Biotechnology Research, Shandong Academy of Agricultural Sciences, Jinan 250100, China
1 shared publication
Latest Publications
- Open Access
- 6 July 2023
- Published by MDPI AG in Microbiology Research
- Vol. 14 (3) , 831-869
3L, Three-Lactobacilli on Recovering of Microbiome and Immune-Damage by Cyclophosphamide Chemotherapy—A Pilot Experiment in Rats
We deal with various strains of Lactobacillus that can maintain the intestinal microbiome of rats treated with cyclophosphamide, an anticancer agent (chemotherapy). We use MiSeq and various types of statistical tests to prove that cyclophosphamide in rats alters the intestinal microbiome, favoring the growth of various fungi that are extremely harmful to intestinal metabolism. On the contrary, when Lactobacillus 3L is administered together with cyclophosphamide, we prove that the microbiome is preserved by having a much better intestinal metabolism.
- 6 July 2023
- Published by MDPI AG in Microbiology Research
- Vol. 14 (3) , 831-869
Open Access3L, Three-Lactobacilli on Recovering of Microbiome and Immune-Damage by Cyclophosphamide Chemotherapy—A Pilot Experiment in Rats
We deal with various strains of Lactobacillus that can maintain the intestinal microbiome of rats treated with cyclophosphamide, an anticancer agent (chemotherapy). We use MiSeq and various types of statistical tests to prove that cyclophosphamide in rats alters the intestinal microbiome, favoring the growth of various fungi that are extremely harmful to intestinal metabolism. On the contrary, when Lactobacillus 3L is administered together with cyclophosphamide, we prove that the microbiome is preserved by having a much better intestinal metabolism.
- Open Access
- 17 February 2022
- Published by MDPI AG in Preprints.org
Lactobacillus on Recovering of Immune-Damage by Chemotherapy (Cancer Treatment)
We demonstrated the role of natural probiotics 3L, 3 Lactobacilli, in the establishment of a strong and sustainable beneficial healthy gut flora, after chemotherapy through experimental results through in vivo model. Using rat CTX model (immunosuppression induced by cyclophosphamide), we suggested some new adjuvant to chemotherapy as drugs + lactobacillus treament. Further, we proposed a new probiotic formulation (L. acidophilus + L. casei + L. plantarum) to be explored in the prevention of health condition loss by alteration of the general immune system, in numerous studies that reported the use of probiotics involving Lactobacillus in the post-chemo or post-surgical procedures. Here, in our study, Illumina MiSeq sequencing was used to generate sequencing data from microbial genomic DNA libraries, which is appreciable to check for the effects of 3L on bacteria. Microbiome analysis, phylogenetic and classification reports, community data have supported the experiments and the results where 3L had strong beneficial effects on the microbiome. Further, the influence on specific metabolic pathways are assisted in deriving the conclusion of the study (use of 3L for cancer therapy) to the mode of action, mechanistically by correcting microbiota composition and enhancing specific gut metabolic functions.
- 17 February 2022
- Published by MDPI AG in Preprints.org
Open AccessLactobacillus on Recovering of Immune-Damage by Chemotherapy (Cancer Treatment)
We demonstrated the role of natural probiotics 3L, 3 Lactobacilli, in the establishment of a strong and sustainable beneficial healthy gut flora, after chemotherapy through experimental results through in vivo model. Using rat CTX model (immunosuppression induced by cyclophosphamide), we suggested some new adjuvant to chemotherapy as drugs + lactobacillus treament. Further, we proposed a new probiotic formulation (L. acidophilus + L. casei + L. plantarum) to be explored in the prevention of health condition loss by alteration of the general immune system, in numerous studies that reported the use of probiotics involving Lactobacillus in the post-chemo or post-surgical procedures. Here, in our study, Illumina MiSeq sequencing was used to generate sequencing data from microbial genomic DNA libraries, which is appreciable to check for the effects of 3L on bacteria. Microbiome analysis, phylogenetic and classification reports, community data have supported the experiments and the results where 3L had strong beneficial effects on the microbiome. Further, the influence on specific metabolic pathways are assisted in deriving the conclusion of the study (use of 3L for cancer therapy) to the mode of action, mechanistically by correcting microbiota composition and enhancing specific gut metabolic functions.